Objective: To describe the spectrum of routine injection practice for botulinum neurotoxin-A (BoNT-A) in the management of cervical dystonia (CD).

Background: The success of each BoNT-A injection procedure is dependent on a number of variables, including: dose, injection volume, muscle selection and number of injection sites. These choices are guided by the patient’s clinical presentation, access to treatment and other factors, including injector training. MetaCD includes data from 2 observational international studies (INTEREST IN CD1 and 2) and 1 US registry (ANCHOR-CD). To our knowledge, this is the largest cohort of CD patients followed in routine clinical practice and provides valuable insights into the spectrum of international clinical practice.

Methods: Descriptive statistics depict the utilisation of BoNT-A at the Baseline/first injection visit.

Results: Data are presented for 1624 (M:517/F:1107) CD subjects treated with BoNT-A. The majority (64.5%) was aged ≥51 years old; 85.3% subjects had been previously treated with BoNT; and 34.6% subjects were receiving other concomitant treatments for CD. Median ⦥ BoNT-A doses (analysed by brand) were: 450U [20–1502U] for abobotulinumtoxinA, 120U [10–500U] for onabotulinumtoxinA and 140U [10–500U] for IncobotulinumtoxinA. Details of injection data are presented in Table 1.

Conclusions: While the median data found in this large international cohort were generally as expected for a population of CD patients presenting for BoNT-A treatment in routine practice, the range of data highlights the potential heterogeneity of clinical practice.

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/highlighting-the-spectrum-of-practice-in-the-routine-management-of-cervical-dystonia-with-botulinum-neurotoxin-a-baseline-injection-practice-data-from-metacd/